Ahead of their graduation earlier this month, two Lake Forest High School students received national recognition for the ...

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Meissner was previously listed in April as a consultant to the RSV vaccines work group for the CDC committee, before Kennedy ...

Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation ...

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to ...

CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Discover how U.S. biotechs can learn from China's success in affordable, high-quality drug development. Read more here.